Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...
The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback